Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus
Open Access
Abstract
The COVID-19 pandemic has had a profound impact on societies, public health, healthcare systems, and the world economy. With over 771 million people infected worldwide and a staggering death toll exceeding 6,960,783 as of 4 October 2023 (according to the World Health Organization), the urgency for a solution was paramount. Since the outbreak, the demand for immediate treatment for COVID-19 viral infection, as well as for effective vaccination against this virus, was soaring, which led scientists, pharmaceutical/biotech companies, government health agencies, etc., to think about a treatment strategy that could control and minimize this outbreak as soon as possible. Vaccination emerged as the most effective strategy to combat this infectious disease. For vaccination strategies, any conventional vaccine approach using attenuated live or inactivated/engineered virus, as well as other approaches, typically requires years of research and assessment. However, the urgency of the situation promoted a faster and more effective approach to vaccine development against COVID-19. The role of nanotechnology in designing, manufacturing, boosting, and delivering vaccines to the host to counter this virus was unquestionably valued and assessed. Several nanoformulations are discussed here in terms of their composition, physical properties, credibility, and applications in past vaccine development (as well as the possibility of using those used in previous applications for the generation of the COVID-19 vaccine). Controlling and eliminating the spread of the virus and preventing future recurrence requires a safe, tolerable, and effective vaccine strategy. In this review, we discuss the potential of nanoformulations as the basis for an effective vaccine strategy against COVID-19.Keywords
Funding Information
- NIH-NIGMS (5SC3GM142001, P20 GM103424-17, TL4GM118968, 245909)
- NIGMS (5SC3GM142001, P20 GM103424-17, TL4GM118968, 245909)
- NIH BUILD program (5SC3GM142001, P20 GM103424-17, TL4GM118968, 245909)
- Louisiana Cancer Research Consortium (LCRC), RCMI and LS-LAMP (5SC3GM142001, P20 GM103424-17, TL4GM118968, 245909)
This publication has 117 references indexed in Scilit:
- Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infectionJournal of Controlled Release, 2013
- Novel Nanosomes for Gene Delivery to Plasmodium falciparum-infected Red Blood CellsScientific Reports, 2013
- Viral vectors for vaccine applicationsClinical and Experimental Vaccine Research, 2013
- Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral ResponsesPLOS ONE, 2012
- Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria VaccinePLOS ONE, 2012
- Design of a Protective Single-Dose Intranasal Nanoparticle-Based Vaccine Platform for Respiratory Infectious DiseasesPLOS ONE, 2011
- Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responsesNature Materials, 2011
- Hyaluronan as an Immune Regulator in Human DiseasesPhysiological Reviews, 2011
- Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cellsJournal of Immunological Methods, 2010
- Characterization of Stability and Nasal Delivery Systems for Immunization with Nanoemulsion-Based VaccinesJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010